SCHEMBL4097596

SCHEMBL4097596

CC(C)(C)c1ccc(C(NC(=O)Nc2ccc(SC(F)(F)F)cc2)c2ccc(C(=O)Nc3nn[nH]n3)cc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 4/20 0.57
GCGR P47871 8/20 0.52
ADCY6 O43306 1/20 0.52
ADCY3 O60266 1/20 0.52
ADCY9 O60503 1/20 0.52
ADCY5 O95622 1/20 0.52
ADCY8 P40145 1/20 0.52
ADCY7 P51828 1/20 0.52
ADCY2 Q08462 1/20 0.52
ADCY1 Q08828 1/20 0.52
ADCY4 Q8NFM4 1/20 0.52
NR1H4 Q96RI1 4/20 0.42
EPHX2 P34913 2/20 0.42
GIPR P48546 3/20 0.41
FPR2 P25090 1/20 0.38
LMNA P02545 1/20 0.37
POLB P06746 1/20 0.37
GAA P10253 1/20 0.37
HTT P42858 1/20 0.37
HDAC3 O15379 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4088384 0.86 GCGR (0.62) TRPV1GCGRADCY6ADCY3ADCY9
SCHEMBL4091185 0.86 GCGR (0.58) TRPV1GCGRADCY6ADCY3ADCY9
SCHEMBL4095552 0.85 GCGR (0.47) TRPV1GCGRADCY6ADCY3ADCY9
SCHEMBL4086516 0.82 GCGR (0.50) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL4085596 0.82 GCGR (0.48) TRPV1GCGRADCY6ADCY3ADCY9
SCHEMBL4086742 0.82 GCGR (0.51) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL4081695 0.82 NR1H4 (0.52) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL4097734 0.80 GCGR (0.51) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL4082063 0.80 GCGR (0.51) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL4091978 0.79 GCGR (0.51) GCGRADCY6ADCY3ADCY9ADCY5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 US disclosed
EP-1183229-B1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK AS (DK) 2005-10-26 EP disclosed
US-20050203108-A1 Glucagon antagonists/inverse agonists PFIZER INC 2005-09-15 US disclosed
US-6875760-B2 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2005-04-05 US disclosed
US-6503949-B1 Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity NORO NORDISK A/S (DK) 2003-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203108-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR TRPV1 1930/4885GCGR 3/4885ADCY6 956/4885
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists GLP1R, GPR119, GCGR TRPV1 1930/4885GCGR 3/4885ADCY6 956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.